封面
市場調查報告書
商品編碼
1471071

血漿分餾市場:按產品、應用和最終用戶分類 - 2024-2030 年全球預測

Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030

出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

血漿分餾市場規模預計2023年為355.2億美元,2024年達389.5億美元,預計2030年將達到712.7億美元,複合年成長率為10.45%。

血漿分餾是指收集、分離和精製人類血漿中存在的各種必需成分,主要包括白蛋白、免疫球蛋白、凝血因子和其他蛋白質。這些成分在醫學上有許多用途,包括血友病治療、免疫疾病治療、創傷治療支持、神經治療和其他罕見疾病。由於原始血漿是多種救生治療的關鍵組成部分,對原始血漿的需求正在穩步成長。這種激增是由於人口老化和免疫疾病盛行率上升所致,這些疾病更容易患上需要血液治療的慢性疾病。此外,患者對血液相關疾病的認知不斷提高也大大促進了該市場的擴張。然而,政府對血漿分餾和替代重組療法的嚴格監管可能會阻礙市場需求。生產技術的新進步將進一步增加該領域參與者的商機。此外,預計各相關人員之間的策略聯盟將推動產業內的創新研究工作,提供新穎的解決方案並在預測期內創造利潤豐厚的市場機會。

主要市場統計
基準年[2023] 355.2億美元
預測年份 [2024] 389.5億美元
預測年份 [2030] 712.7億美元
複合年成長率(%) 10.45%

在產品免疫球蛋白精製中增加血漿分餾的使用

白蛋白是一種主要的血漿蛋白,對於調節血液容量和運輸多種物質(包括荷爾蒙、藥物和營養物質)非常重要。免疫球蛋白製劑主要用於治療低血容、低白蛋白血症和嚴重燒傷。凝血因子濃縮物對於治療A型血友病等出血性疾病至關重要,並且可以促進血管性血友病的癒合。免疫球蛋白是透過中和細菌和病毒等病原體在人體免疫反應中發揮重要作用的抗體,通常用於原發性免疫力缺乏疾病、發炎疾病、自體免疫疾病和某些類型的癌症的治療。蛋白酶抑制劑對於治療遺傳性血管性水腫 (HAE) 至關重要。遺傳性血管性水腫是一種週期性遺傳性疾病,其特徵是身體不同部位反覆發作嚴重腫脹。這些抑制劑可阻斷蛋白酶的作用,從而在遺傳性血管性水腫 (HAE) 發作期間引起發炎和血管滲透性。

應用 擴大在血液疾病治療的應用

在重症加護中,血漿分餾產品對於治療敗血症、燒傷和創傷等危及生命的疾病至關重要。血漿分餾在血液腫瘤學中具有重要應用,可支持血液相關癌症的治療和化療。血液學涉及血友病和馮維勒布蘭德病 (VWD) 等血液疾病的預防、診斷和治療。含有 IVIG 的血漿分餾產品擴大用於治療神經系統疾病,如Guillain-Barré二氏症候群、慢性脫髓鞘多發性神經炎(CIDP) 和多發性硬化症。在呼吸系統醫學中,血漿分餾可用於治療 α-1 抗胰蛋白酶缺乏症 (AATD) 和急性呼吸窘迫症候群(ARDS) 等呼吸系統疾病。血漿分餾用於風濕病學,主要透過使用 IVIG 來治療自體免疫和發炎疾病。

最終用戶:血漿分餾廣泛用於臨床研究實驗室,以確保血漿衍生產品的安全性和有效性。

學術和研究機構從事基礎研究,以提高我們對血漿蛋白及其治療潛力的了解。此細分市場的主要需求包括用於蛋白質表徵研究的高純度血漿分餾、用於發現的先進分餾技術以及獲得可靠的原料來源。臨床研究實驗室對於測試和檢驗製程和產品至關重要。我們進行測試以確保血漿衍生產品的安全性和有效性,評估患者影響並收集資料以支持監管核准。這些實驗室參與產品開發的臨床前和臨床階段。

區域洞察

由於其完善的醫療基礎設施、免疫不全症的高盛行率以及不斷成長的老年人口,美洲在血漿分餾市場中佔有重要地位。在歐洲,歐盟國家擁有強而有力的法規結構來管理血漿分餾產業。歐洲藥品管理局 (EMA) 負責監管血液產品的製造方法並監督品質標準,是該地區市場需求的主要推動者。由於收入的增加和醫療保健服務的擴大,中東和非洲地區提供了利潤豐厚的機會。在亞太地區,快速的都市化和經濟發展正在推動醫療基礎設施投資,市場格局正在向新興市場演變。此外,亞太地區各國政府也越來越關注血液安全法規,為市場進入者創造了機會。

FPNV定位矩陣

FPNV定位矩陣對於評估血漿分餾市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。

市場佔有率分析

市場佔有率分析是一種綜合工具,可對血漿分餾市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解:

1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。

3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題:

1.血漿分餾市場的市場規模與預測是多少?

2.血漿分餾市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些?

3.血漿分餾市場的技術趨勢和法規結構是什麼?

4.血漿分餾市場主要廠商的市場佔有率為何?

5.進入血漿分餾市場適合的形式和策略手段是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 改善血漿治療的可及性並在各個治療領域大量使用免疫球蛋白
      • 政府努力增加血漿採集
      • 隨著世界各地老年人數量的增加,採血設施的數量也增加。
    • 抑制因素
      • 存在對目前病毒去活化治療具有抗藥性的新病原體
    • 機會
      • 製程開發技術的不斷進步以改進配方
      • 新臨床試驗的爆炸性使用以及血漿治療研發活動的擴展
    • 任務
      • 關於血漿分餾和替代重組療法的存在的嚴格政府法規
  • 市場區隔分析
    • 產品:增加血漿分餾在免疫球蛋白精製的使用
    • 用途:越來越多用於治療血液疾病
    • 最終用戶:血漿分餾廣泛用於臨床研究實驗室,以確保血漿衍生產品的安全性和有效性。
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章血漿分餾市場:依產品

  • 白蛋白
  • 濃縮凝血因子
  • 免疫球蛋白
  • 蛋白酶抑制劑

第7章血漿分餾市場:依應用分類

  • 加護治療
  • 血液腫瘤學
  • 血液學
  • 神經病學
  • 呼吸系統醫療設備
  • 風濕病學

第8章血漿分餾市場:依最終用戶分類

  • 學術研究所
  • 臨床研究實驗室

第9章美洲血漿分餾市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太血漿分餾市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲/中東/非洲血漿分餾市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
    • Grifols 埃及運送第一批由埃及捐贈血漿製成的血漿藥物
    • CSL 耗資 4.7 億美元的血漿分餾設施在德國馬爾堡開業
    • 武田投資 1000 億日圓在日本新血漿分餾產品生產設施
    • Kedrion 在沙烏地阿拉伯的血漿分餾研討會上發表演講
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4312A385A58A

[197 Pages Report] The Plasma Fractionation Market size was estimated at USD 35.52 billion in 2023 and expected to reach USD 38.95 billion in 2024, at a CAGR 10.45% to reach USD 71.27 billion by 2030.

Plasma fractionation refers to collecting, separating, and purifying various essential components present in human plasma, primarily including albumin, immunoglobulins, coagulation factors, and other proteins. These components have many applications in medical treatments, such as hemophilia therapy, immunity disorders treatment, wound healing support, neurology therapy, and other rare diseases. The demand for source plasma has been steadily increasing due to its role as a vital ingredient in several life-saving therapies. This surge can be attributed to an aging population prone to chronic illnesses requiring blood-based therapies and the rising prevalence of immune disorders. In addition, rising awareness about blood-related diseases among patients contributes significantly to this market's expansion. However, stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies may hamper the market demand. New advancements in production technology further boost opportunities for the players involved in this field. Moreover, strategic collaborations among various stakeholders drive innovative research work within the industry that provides novel solutions and is expected to create a lucrative market opportunity in the forecasted period.

KEY MARKET STATISTICS
Base Year [2023] USD 35.52 billion
Estimated Year [2024] USD 38.95 billion
Forecast Year [2030] USD 71.27 billion
CAGR (%) 10.45%

Product: Rising use of plasma fractionation for immunoglobulins purification

Albumin is a major plasma protein critical in regulating blood volume and transporting various substances, including hormones, drugs, and nutrients. It primarily treats hypovolemia (low blood volume), hypoalbuminemia (low albumin levels), and severe burns. Coagulation factor concentrates are essential for treating bleeding disorders such as hemophilia A & B and von Willebrand disease and replace missing or deficient clotting factors, preventing excessive bleeding and promoting proper wound healing. Immunoglobulins are antibodies that play a crucial role in the body's immune response by neutralizing pathogens such as bacteria and viruses and are used to treat primary immunodeficiency diseases, inflammatory and autoimmune disorders, and certain types of cancer. Protease inhibitors are essential for managing hereditary angioedema (HAE), a periodic genetic condition characterized by recurrent episodes of severe swelling in various body parts. These inhibitors block the action of proteases responsible for inflammation and vascular permeability during hereditary angioedema (HAE) attacks.

Application: Proliferating use to treat hematological disorders

In the critical care setting, plasma fractionation products are vital for treating life-threatening conditions such as sepsis, burns, and trauma. Plasma fractionation has significant applications in hemato-oncology for managing blood-related cancers and supporting chemotherapy treatments. Hematology involves the prevention, diagnosis, and treatment of blood diseases such as hemophilia or von Willebrand disease (VWD). Plasma fractionation products including IVIG are increasingly used in treating neurological conditions, including Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and multiple sclerosis. In pulmonology, plasma fractionation helps in managing respiratory diseases such as alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS). Plasma fractionation is utilized in rheumatology primarily through the use of IVIG to manage autoimmune and inflammatory disorders.

End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products

Academic & research institutes are engaged in basic research to advance the understanding of plasma proteins and their therapeutic potential. The key needs for this segment include high-purity plasma fractions for protein characterization studies, advanced fractionation techniques that can lead to discoveries, and access to reliable sources of raw material. Clinical research laboratories are essential for testing and validating plasma fractionation processes and products. They conduct trials to ensure the safety and efficacy of plasma-derived products, assess their impact on patients, and gather data to support regulatory approval. These laboratories are involved in both pre-clinical and clinical stages of product development.

Regional Insights

The Americas has a significant market presence in the plasma fractionation market due to a well-established healthcare infrastructure, high prevalence of immunodeficiency diseases, and an increasing geriatric population. In Europe, EU countries have a strong regulatory framework governing the plasma fractionation industry. The European Medicines Agency (EMA) regulates manufacturing practices and oversees quality standards for blood-derived products, significantly driving the region's market demand. The MEA region presents lucrative opportunities due to rising incomes and expanding access to healthcare services. The Asia-Pacific observed a developing landscape in the plasma fractionation market owing to rapid urbanization and economic development that is driving investments in healthcare infrastructure. Additionally, there is an increasing focus on blood safety regulations by governments in the APAC region, presenting opportunities for market players.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Plasma Fractionation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Plasma Fractionation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.

Market Segmentation & Coverage

This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Albumin
    • Coagulation Factor Concentrates
      • Factor IX
      • Factor VIII
      • Factor XIII
      • Fibrinogen Concentrates
      • Prothrombin Complex Concentrate
      • Von Willebrand Factor
    • Immunoglobulin
      • Intravenous Immunoglobulin
      • Subcutaneous Immunoglobulin
    • Protease Inhibitors
  • Application
    • Critical Care
    • Hemato-Oncology
    • Hematology
    • Neurology
    • Pulmonology
    • Rheumatology
  • End-User
    • Academic & Research Institutes
    • Clinical Research Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Plasma Fractionation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Plasma Fractionation Market?

3. What are the technology trends and regulatory frameworks in the Plasma Fractionation Market?

4. What is the market share of the leading vendors in the Plasma Fractionation Market?

5. Which modes and strategic moves are suitable for entering the Plasma Fractionation Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
      • 5.1.1.2. Government initiatives to increase plasma collection
      • 5.1.1.3. Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Presence of new pathogenic agents that resist the present viral inactivation treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous advancements in process development technology for improved formulations
      • 5.1.3.2. Exponential utilization in new clinical trials and growing R&D activities in plasma treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising use of plasma fractionation for immunoglobulins purification
    • 5.2.2. Application: Proliferating use to treat hematological disorders
    • 5.2.3. End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Plasma Fractionation Market, by Product

  • 6.1. Introduction
  • 6.2. Albumin
  • 6.3. Coagulation Factor Concentrates
  • 6.4. Immunoglobulin
  • 6.5. Protease Inhibitors

7. Plasma Fractionation Market, by Application

  • 7.1. Introduction
  • 7.2. Critical Care
  • 7.3. Hemato-Oncology
  • 7.4. Hematology
  • 7.5. Neurology
  • 7.6. Pulmonology
  • 7.7. Rheumatology

8. Plasma Fractionation Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Clinical Research Laboratories

9. Americas Plasma Fractionation Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Plasma Fractionation Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Plasma Fractionation Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations
    • 12.3.2. CSL's USD470 Million Plasma Fractionation Facility Opens in Marburg, Germany
    • 12.3.3. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
    • 12.3.4. Kedrion presented at plasma fractionation workshop in Saudi Arabia
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PLASMA FRACTIONATION MARKET RESEARCH PROCESS
  • FIGURE 2. PLASMA FRACTIONATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PLASMA FRACTIONATION MARKET DYNAMICS
  • FIGURE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PLASMA FRACTIONATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA FRACTIONATION MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ALBUMIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR IX, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR VIII, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR XIII, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FACTOR XIII, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FIBRINOGEN CONCENTRATES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY FIBRINOGEN CONCENTRATES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY VON WILLEBRAND FACTOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY VON WILLEBRAND FACTOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CRITICAL CARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATO-ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATO-ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY HEMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PULMONOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY CLINICAL RESEARCH LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY PLASMA FRACTIONATION MARKET SIZE, BY COAGULATION FACTOR CONCENTRATES, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY PLASMA FRACTIONATION MARKET SIZE, BY IMMUNOGLOBULIN, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2